Targets › MAPK11
1 program from 1 company in 41 trials: 31 Phase 2, 7 Phase 1, 3 Phase 3; Oncology; next expected readout Apr 2028.
Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK11 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors. (UniProt, Q15759)
Open in Phaseline: the race on MAPK11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bayer | Regorafenib (BAY73) Tyrosine-protein kinase ABL inhibitor; Serine/threonine-protein kinase RAF inhibitor; Stem cell growth factor receptor inhibitor | ABL1, RAF1, KIT, FGFR1, MAPK11 | Phase 2 | Solid Malignant Tumors; Metastatic Colorectal Cancer (mCRC); Colorectal Cancer Liver Metastases; Colorectal Cancer Metastatic … | Apr 2028 |
Hepatocellular Carcinoma (3) Colorectal Cancer Metastatic (2) Melanoma Stage III (2) Gastrointestinal Stromal Tumors (2) Colorectal Cancer (2) Metastatic Colorectal Cancer (2) Solid Malignant Tumors (1) Metastatic Colorectal Cancer (mCRC) (1) Colorectal Cancer Liver Metastases (1) Osteosarcoma (1) Liver Metastases (1) Liver Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.